


ALT-802 Fact Sheet



STAR™ Fusion Drugs for Cancer: ALT-802 is a fusion of a p53-specific single-chain T-cell receptor (scTCR) to the heavy chain constant domain of human IgG1, providing the Fc effector domain to invoke ADCC against p53⁺ cancer cells. This product effectively is an antibody-like molecule capable of targeting p53⁺ tumors. As a result of the fusion to the heavy chain constant domain, this protein is capable of forming dimers and specifically binds p53⁺ tumor cells. The protein also has potent antitumor effects in metastatic tumor and well-established subcutaneous tumor models and can mediate target cell killing by an ADCC-like mechanism. We have compared a variety of different TCR/Ig fusion formats including the full IgG1 C_H1-C_H2-C_H3 region and a smaller C_H2-C_H3 domain in these models. The full TCR/IgG1 is more active than the C_H2-C_H3 fusion in mediating ADCC-like activity against p53-peptide bearing target cells. For instance, in a human non-small cell lung tumor experimental metastasis model in nude mice, the p53-specific TCR/IgG1 full-length fusion was more

effective at reducing the number of metastatic nodules in the lungs than the p53-specific TCR/Ig C_H2-C_H3 fusion. Moreover, combining the TCR/IgG1 fusion with cisplatin-based chemotherapy, the standard of care treatment for patients with non-small cell lung cancer, was shown to have improved efficacy reducing lung tumors in the lung tumor metastasis model and in nude mice bearing subcutaneous human p53⁺ melanoma tumors. Pharmacokinetic analysis has also been conducted indicating that ALT-802 has a half life of approximately 38 hours in transgenic HLA-A*0201 mice, 47 hrs in CD1 mice and 27.7 hours in cynomolgus monkeys, which is similar to that of other therapeutic antibodies.

In summary, single-chain TCRs linked to the IgG1 heavy chain fusions behave like antibodies but possess the ability to recognize antigens derived from intracellular targets. These fusion proteins represent a novel group of immunotherapeutics that have the potential to expand the range of tumors available for targeted therapies beyond those currently addressed by the conventional antibody-based approach. In preparation for additional preclinical and potential clinical studies using the p53-specific TCR/IgG1 fusion, we have generated high-level expression CHO cell lines for serum-free suspension production of ALT-802. Preclinical pharmacology and toxicity studies are underway.

Since this product shows synergistic anti-tumor activity against xenograft NSCLC when used in combination with cisplatin, the first-line, standard-of-care treatment for NSCLC, initial clinical development will focus on this indication. An IND is to be submitted for ALT-802 in 2011 and a phase I trial is planned for late 2011 for patients with late-stage p53⁺ NSCLC.

Altor is seeking a partner that will license, complete clinical development and commercialize the product.

The following non-confidential information can be provided and sent as e-mail attachments:

1. Publication:
 - Mosquera, L. A., K. F. Card, S. A. Price-Schiavi, H. J. Belmont, B. Liu, J. Builes, X. Zhu, P. A. Chavaillaz, H. I. Lee, J. A. Jiao, J. L. Francis, A. Amirkhosravi, R. L. Wong, and H. C. Wong. 2005. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. *J Immunol* 174:4381.
2. Altor White Papers relating to:
 - p53 as a target
 - STAR-Ck Technology
 - STAR-Ck Mechanism of Action
 - STAR Diagnostics

For more information, contact Altor BioScience Corporation at (954) 443-8600, ext. 832 or e-mail deantaylor@altorbioscience.com. Further documentation can be provided upon execution of a confidentiality agreement.